IMTX - Immatics NV logo

IMTX

Immatics NV

Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors. Its product pipeline includes various cell therapies and bispecifics in clinical trials, partnering with institutions to enhance T cell therapies.

⚕️ Healthcare NASDAQ Listed 2020 € EUR
$1,000 invested 5 years ago $804today

Score Overview

1 Year
Score
Net Growth-9.14%
Net TrendShrank
Net Income Consistency
Rev Growth-22.73%
Rev TrendShrank
Revenue Consistency
5 Years
Score3.0
Net Growth-125.54%
Net Trend40%
Net Income Consistency
Rev Growth7.29%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth6.52%
Net Trend50%
Net Income Consistency
Rev Growth19.34%
Rev Trend50%
Revenue Consistency

See the full market ranking →

Immatics NV fundamental performance

Between 2020 and 2025, revenue grew from € 31M to € 48M and net income went from -€ 229M to -€ 196M. Revenue increased in 2 of those 5 years; net income in 2.

Immatics NV currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 9.71
1 Year2025-08-12
$ 6.4251.25%
5 Years2021-08-12
$ 12.08-19.62%
All Time2020-07-02
$ 15.05-35.48%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026€ 37M-€ 214M€ 454M
2025€ 48M-€ 196M€ 469M
2024€ 155M€ 15M€ 604M
2023€ 53M-€ 96M€ 425M
2022€ 172M€ 37M€ 362M
2021€ 34M-€ 95M€ 145M
IPO2020€ 31M-€ 229M€ 231M

Explore beyond IMTX

You're looking at Immatics NV. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies